Drug intelligence / Profile preview

AISA-022

Development stage: Unknown
Lead developer: Aisa Pharma
Modality: Small Molecules

Overview

AISA-022 is a small molecule drug in preclinical development by Aisa Pharma for the treatment of Raynaud disease (Raynaud's phenomenon). The specific mechanism of action and molecular target for AISA-022 have not been publicly disclosed. It is part of a pipeline focused on nervous system diseases, with Raynaud disease as its primary indication. No clinical trial or detailed pharmacological data are available at this time.

Beyond the preview

Go deeper on AISA-022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AISA-022.

Explore the full profile